East Asia
China
Large tertiary centres with high case volumes and active programmes in cellular therapy, oncology and stroke intervention.
Country intelligence
Specialist strengths
Oncology · CAR-T & cellular therapy · Stroke intervention · Hematology · Sickle cell programmes
Language support
Mandarin, English (international patient departments)
Travel considerations
Long-haul from North America, Europe and Africa; internal transfers usually required.
Visa considerations
Medical visa pathway with hospital invitation letter; timelines vary by consulate.
Connectivity
Major hubs in Beijing, Shanghai, Guangzhou.
Recovery environment
CrossCare Recovery Suites™ China network.
Teleconsultation
Pre-travel teleconsultation available with several partner centres.
Verification
Partner hospitals reviewed under the CrossCare Global Trust Layer™ before referral.
Advanced pathways patients ask about here
CAR-T & Cellular Therapy
Country-specific availabilityEngineered immune-cell therapies used in selected blood cancers, with eligibility decided by the treating haematology team.
Approved indications differ by country. Some programmes are only accessible inside a clinical trial.
Proton Therapy
Country-specific availabilityParticle radiotherapy used in selected tumours where sparing surrounding tissue matters.
Limited number of centres worldwide; suitability is decided by radiation oncology.
Stroke Intervention
Established treatmentTime-critical intervention and post-stroke rehabilitation pathways.
Acute stroke is an emergency — contact local emergency services first.
Bone Marrow / Stem Cell Transplantation
Established treatmentAutologous and allogeneic transplantation programmes with donor coordination.
Donor matching and eligibility are determined by the transplant centre.
Sickle Cell Treatment
Country-specific availabilityDisease-modifying therapy, transfusion programmes and curative transplant pathways.
Gene-therapy options are limited and access is strictly regulated.
Gene & Cell Therapy
Emerging / investigationalTherapies modifying or replacing cellular material in selected genetic and haematological conditions.
Frequently investigational. Never described as a cure; informed consent and regulatory status must be reviewed.
Advanced Diabetes Care
Established treatmentStructured metabolic programmes, technology-supported control and complication management.
Programme design remains with the treating endocrinologist.
Regenerative Medicine
Emerging / investigationalCell-based and biologic approaches in selected orthopaedic and degenerative conditions.
Evidence varies widely by indication. Claims of cure should be treated with caution.
Rare Disease Programmes
Country-specific availabilitySpecialist referral centres for undiagnosed and rare conditions.
Access usually begins with a documented case review.
Clinical Trials
Clinical trialResearch studies with defined eligibility criteria, oversight and informed consent.
Participation is never guaranteed and is decided by the trial investigator.
Compare with other destinations
Healthcare decisions should be based on clinical appropriateness — not price alone. CrossCare helps patients understand their options, but diagnosis and treatment recommendations must come from qualified healthcare professionals. Estimates are for planning purposes and are not guarantees. Final pricing must be confirmed by the treating healthcare provider and relevant travel/service providers.